-

Half-Year Liquidity Contract Statement for Valerio Therapeutics

PARIS--(BUSINESS WIRE)--Regulatory News:

Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO)

Under the liquidity contract entered into between Valerio Therapeutics and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2023:

- 368,174 shares
- € 144,918.05

- Number of executions on buy side on semester: 324
- Number of executions on sell side on semester: 244
- Traded volume on buy side on semester: 304,205 shares for € 69,976.87
- Traded volume on sell side on semester: 223,191 shares for € 56,117.81

As a reminder :

  • the following resources appeared on the last half year statement on 30 June 2023 on the liquidity account:

- 287,160 shares
- € 156,554.06

- Number of executions on buy side on semester: 509
- Number of executions on sell side on semester: 492
- Traded volume on buy side on semester: 634,648 shares for € 258,705.74
- Traded volume on sell side on semester: 923,185 shares for € 402,719.91

  • the following resources appeared on the liquidity account when the activity started:

- 87,612 shares
- € 196,423.24

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

Contacts

Valerio Therapeutics S.A.

Valerio Therapeutics

BOURSE:ALVIO
Release Versions
EnglishFrench

Contacts

Valerio Therapeutics S.A.

More News From Valerio Therapeutics

Valerio Therapeutics Announces Binding Term-Sheet for Collaboration and Exclusive License With Seed-Stage Biotech Company

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the “Company”), announces that it has entered into a binding term-sheet with a biotech company currently operating in stealth mode, setting out the principal terms of a collaboration and exclusive worldwide license. The final terms remains subject to the signin...

Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the “Company”), today announces the launch of InVimmune, a new company dedicated to developing differentiated in vivo cell therapy approaches with potential applications across oncology, fibrosis, autoimmune diseases and additional indications. InVimmune’s firs...

Valerio Therapeutics Publishes Its 2025 Annual Results and Annual Financial Report, and Confirms the Strategic Transformation of Its Operating Model

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the “Company”), today announces the publication of its annual results and annual financial report for the 2025 financial year, [available on its website under the “Financial Information” section], and outlines the key pillars of its strategic roadmap. “2025 was...
Back to Newsroom